

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Walter ELGER et al.

Serial No.: 09/744,574 *pdh*

Filed: 5 April 2001

For: USE OF BIOGENIC ESTROGEN SULFAMATES FOR HORMONE REPLACEMENT THERAPY



Group Art Unit: 1617

Examiner: M. Bahar

REPLY

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

In response to the Office Action dated June 20, 2001, please consider the remarks.

RECEIVED
FEB 04 2002
TECH CENTER 1600/2900

In the Claims

Please cancel claims 1-7 without prejudice and disclaimer.

Please add the following new claims:

--8. A method of achieving hormone replacement therapy in a woman comprising intermittently orally administering an estrogen sulfamate at a dosage of 20-300 µg/day in intervals of 2 or 3 days; 0.5-5.0 mg/day in intervals of 5-10 days; or 2.0-20 mg/day in intervals of 20-40 days.

9. A method according to claim 8, wherein the estrogen sulfamate is estrone sulfamate, estradiol sulfamate, estriol sulfamate, N-acylsulfamate of estrone, estradiol or estriol having an acyl chain of up to 7 C atoms or mixtures thereof.

10. A method according to claim 8, wherein the intermittent oral administration is carried out at an interval of 2 to 40 days between administrations.

I hereby certify that this correspondence is being deposited with the U.S. Postal Services as First Class Mail in an envelope addressed To: Commissioner of Patents and Trademarks,
Washington, D.C. 20231 On: December 20, 2001
Name: CESAR A. HERTZEN
Signature: CAS
Date: 12/20/2001